达格列净改善 2 型糖尿病合并心力衰竭患者急性心肌损伤的临床观察

Clinical effect of dapagliflozin on acute myocardial injury in patients with type 2 diabetes mellitus and heart failure

摘要:

目的 观察达格列净对 2 型糖尿病（T2DM）合并心力衰竭患者急性心肌损伤的效果。方法 68 例T2DM 合并心力衰竭患者分为观察组（36 例）和对照组（32 例）；两组均使用心力衰竭基础治疗，观察组联用达格列净。比较两 组心肌损伤标志物和炎症因子水平的变化、主要不良心血管事件（MACE）及心力衰竭复发再住院次数。结果 观察组氨 基末端脑钠肽前体、高灵敏肌钙蛋白T、TNF-α、IL-1β、IL-6、C反应蛋白水平及MACE发生率、心力衰竭复发再次住院率 明显低于对照组（P<0.01 或 0.05）。结论 达格列净可减轻T2DM合并心力衰竭患者急性心肌损伤及炎症因子水平，改 善心力衰竭。

Abstract:

Objective To observe the effect of dapagliflozin on acute myocardial injury in patients with type 2 diabetes mellitus (T2DM) and heart failure. Methods Sixty-eight patients with T2DM and heart failure were treated with conventional anti-heart failure therapy (n=32, control group) or combined dapagliflozin (n=36, observation group). Myocardial injury markers, inflammatory cytokines, major adverse cardiovascular events (MACE), and rehospitalization of recurrent heart failure were compared between two groups. Results Compared with control group, levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitivity cardiac troponin T (Hs-TnT), TNF-α, IL-1β, IL-6, C-reactive protein (CRP), MACE, and rehospitalization of recurrent heart failure were lower in observation group (P<0.01 or 0.05). Conclusion Dapagliflozin can improve acute myocardial injury and inflammatory cytokines in patients with T2DM and heart failure.